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Abstract
Background: Long-term conditions (LTCs) are important determinants of quality of life and healthcare expen-
diture worldwide. Whilst multimorbidity is increasingly the norm in primary care, clinical guidelines and the 
delivery of care remain focused on single diseases, resulting in poorer clinical outcomes. Osteoarthritis, and 
anxiety and/or depression frequently co-occur with other LTCs, yet are seldom prioritized by the patient or 
clinician, resulting in higher levels of disability, poorer prognosis, and increased healthcare costs. Objective: 
To examine the feasibility and acceptability of an integrated approach to LTC management, tackling the under-
diagnosis and under-management of osteoarthritis-related pain and anxiety and/or depression in older adults 
with other LTCs in primary care. Design: The ENHANCE study is a pilot stepped-wedge cluster random-
ized controlled trial to test the feasibility and acceptability of a nurse-led ENHANCE LTC review consultation 
for identifying, assessing, and managing joint pain, and anxiety and/or depression in patients attending LTC 
reviews. Specific objectives (process evaluation and research outcomes) will be achieved through a theoretically 
informed mixed-methods approach using participant self-reported questionnaires, a medical record review, an 
ENHANCE EMIS template, qualitative interviews, and audio recordings of the ENHANCE LTC review. 
Discussion: Success of the pilot trial will be measured against the level of the primary care team engagement, 
assessment of training delivery, and degree of patient recruitment and retention. Patient satisfaction and treat-
ment fidelity will also be explored.
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Background and rationale
Long-term conditions (LTCs) are, with their rising 
prevalence, increasingly important determinants of 
quality of life (QoL) and healthcare costs in populations 
worldwide. Over a quarter of the population of England 
(15.4 million people) has at least one LTC [1]. Domain 2 
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of the National Health Service (NHS) outcomes frame-
work has adopted the House of Care as a framework 
to enhance the QoL for people with LTCs [2], and the 
UK National Institute for Health and Care Excellence 
(NICE) publish guidance to help clinicians keep abreast 
of current recommendations and evidence-based care 
for specific LTCs and to guide commissioning decisions; 
however, clinical guidelines usually focus on single con-
ditions in isolation. Other major initiatives to improve 
quality of care and achieve better health for people with 
LTCs include the Chronic Care Model [3] and the NHS 
and Social Care Long-Term Conditions Model [4], both 
of which highlight key system components that need to 
be addressed, including delivery-system design, decision 
support, clinical information systems and self-manage-
ment support.
Patients with LTCs are predominantly managed 
in primary care by general practitioners (GPs) and by 
practice nurses, where they utilize 50% of all appoint-
ments [1]. Other practitioners may be involved in wider 
primary care multidisciplinary teams and services, 
including physiotherapists, pharmacists, mental health 
practitioners in primary care mental health teams or 
Improving Access to Psychological Therapies (IAPT) 
services [5], and other allied health professionals. Pri-
mary care is increasingly seen as the optimal setting to 
deliver care for people with multiple LTCs because of 
its generalist approach, accessibility (often the first point 
of contact), efficiency and ability to identify the health 
needs of the community, and ensuring that there are ser-
vices in place to manage those needs [1].
Increasingly, people have multimorbidity, defined as 
the co-occurrence of two or more LTCs in one person 
[1]. The number of people with three or more condi-
tions is expected to increase from 1.9 million in 2008 to 
2.9 million in 2018 [1]. Patients with several LTCs have 
poorer QoL and clinical outcomes, longer hospital stays, 
are more costly to the health service [6], and may expe-
rience poorer continuity of care [7], polypharmacy [8], 
and greater treatment burden [9,10]. Clinical decision-
making is more difficult in patients with multimorbidity 
because clinicians and patients often struggle to bal-
ance the risks and benefits of multiple recommended 
treatments [11], and because patient preference rightly 
influences the application of clinical and economic 
evidence [12]. Whilst robust synthesis of clinical and 
economic evidence informs guidance for single condi-
tions, combining recommendations for patients with 
multimorbidity can result in harmful or burdensome 
treatment regimens [13,14].
The current focus on single condition management 
means there are several challenges to identifying which 
groups of patients could receive multimorbidity inter-
ventions. The challenges include working out who 
should identify patients to target, which combinations of 
conditions to target, and at what level of severity [15,16]. 
Smith et al. outline that one approach to this could be 
to take into account those who may not be in need of 
intervention and target those at higher risk of adverse 
outcomes (and most likely to benefit) [16].
Musculoskeletal conditions and mental health prob-
lems are common and frequently co-exist, both with 
each other and with other LTCs. Such conditions tend 
to be under-diagnosed, with priority given by patients 
and clinicians to the other LTCs that are perceived to 
be more important (e.g. diabetes) [17,18]. Osteoarthritis 
(OA) is the most common musculoskeletal condition in 
older adults and is one of the diseases with the highest 
prevalence of comorbidity with other chronic condi-
tions (such as hypertension, cardiovascular diseases, 
obesity, respiratory diseases, and diabetes) [19]. People 
with OA are twice as likely to suffer from heart disease 
and premature mortality as those in the general popula-
tion [20]. This co-existence has implications for health, 
well-being, and the use of healthcare resources, as it 
is estimated that 8.75 million people in the UK have 
sought treatment for OA [21].
Depression is common, can be recurrent and can 
affect anyone, with a prevalence in older people thought 
to be as high as 30% [22]. More than 20% of people with 
an LTC may be depressed [23,24]. Anxiety is also com-
mon in people with LTCs, illustrated by an estimated 
prevalence of 10–42% in people with chronic obstruc-
tive pulmonary disease (COPD) [25] and 45% in those 
with chronic pain [26].
Musculoskeletal and mental health problems are often 
not prioritized by patient or clinician, thus cost-effective 
and clinically beneficial treatments are frequently not 
offered to those in most need. Coventry et al. suggest 
that depression is frequently normalized in the presence 
of LTCs [18], obviating rather than facilitating further 
assessment and management [27]. Furthermore, studies 
have highlighted that symptoms due to OA are often 
not addressed or appropriately managed in primary care 
settings [17,28].
It has been suggested that future work might focus 
on how interventions that draw on the principles of the 
Chronic Care Model, such as collaborative care, could 
support primary care practitioners to better recognize 
and manage depression in patients with other LTCs [18]. 
In addition, primary care consultations need to move 
away from Quality and Outcomes Framework (QOF)-
dominated protocols to offer more holistic care [29]; 
however, long-standing divisions between mental and 
physical health may pose particular problems for both 
clinicians and patients, and for integration into existing 
practice [30]. Smith et al. conducted a systematic review 
of primary care and community-based interventions 
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for multimorbidity and found the results of the studies 
included were mixed [31]. They recognized that while 
improving outcomes is challenging, targeting specific 
risk factors in comorbid conditions or functional dif-
ficulties may be effective [31]. The need to develop and 
test effective and targeted interventions for such popula-
tions was also highlighted [6,31].
The aim of this study is to conduct a pilot stepped-
wedge trial to examine the feasibility and acceptability 
of an integrated approach to LTC management; tack-
ling the under-diagnosis and under-management of 
OA-related joint pain (knee, hip, hand, and foot) and 
anxiety and/or depression in patients aged 45 years 
and over with other LTCs in primary care (asthma/
COPD/hypertension or ischaemic heart disease/dia-
betes), within what we have called the ENHANCE 
LTC review. A mixed-methods approach will be 
used to meet the overall aim and objectives set out 
for this study. This study will report on both pro-
cess and research outcomes enabling the acceptability 
and feasibility of the practice nurse training, fidelity 
of delivery of the ENHANCE LTC review, and suit-
ability for a larger randomized controlled trial (RCT) 
using the stepped-wedge design to be fully assessed. 
The protocol for this study has been reported using the 
Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) recommendations [32]. The 
trial has been developed in accordance with published 
definitions of pilot and feasibility studies [33] and rec-
ommendations for good practice in their design and 
evaluation [16,34–38].
Methods
Trial design and setting
The ENHANCE trial is a pilot stepped-wedge cluster 
RCT [39] set in primary care (see Figure 1). The units 
of randomization are general practices and the units 
of observation are adults aged 45 years and older con-
sulting for their LTC review at participating general 
practices.
According to the stepped-wedge design, each gen-
eral practice recruited to the trial will start by providing 
‘usual care’ (the control period), comprising their rou-
tine LTC reviews. This will be followed by a washout 
period (maximum of 2 weeks) where study recruitment 
will halt to allow the practice nurses to receive training 
in how to deliver the ENHANCE LTC reviews and to 
embed the ENHANCE EMIS template within the prac-
tice IT system. This will take place at a pre-designated 
time point, dependent upon the cluster to which the 
practice has been randomized. The intervention period 
will then commence during which the ENHANCE 
LTC review will be embedded within LTC reviews for 
asthma, COPD, hypertension or ischaemic heart dis-
ease, and diabetes, in up to eight consultations per week 
per practice. It is anticipated that the practices will con-
vert from control to intervention sequentially, every 5 
weeks.
In this pilot cluster RCT, GP practices will be eligible 
to take part if they are: within the geographical areas of 
NHS Stoke-on-Trent Clinical Commissioning Group 
Weeks
1–6 7–11 12–16 17–21 22–27
Practice Step 1 Step 2 Step 3 Step 4
1
2
3
4
Control period (usual care)
Washout period (maximum 2 weeks) where delivery of training and
activation of the ENHANCE EMIS template will take place
Intervention period (the ENHANCE long-term condition review)
Figure 1 Schematic representation of the stepped-wedge design for the ENHANCE pilot trial.
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(CCG) and NHS North Staffordshire CCG, use the 
clinical operating system EMIS Web, and have practice 
nurses who are willing and able to undergo training and 
participate in both the control and intervention phases.
The balance between scientific considerations and the 
need for consent is a recognized issue in cluster trials 
[40]. Following discussion with their practice team, the 
senior GP partner in each practice will provide informed 
consent for the practice to participate, acting as ‘guard-
ian’ for patients and their care. GP practice consent to 
participate will be formalized through written agree-
ments. The care received by eligible patients will be 
dictated by the period (control or intervention) their 
practice is currently delivering. The practice nurse will 
introduce the research study and hand out a study pack 
to all patients booked into the dedicated consultations 
who are deemed eligible at the start of the LTC review. 
The study packs are identical for both control and inter-
vention periods and will include: an invitation letter 
from the practice to participate in the study; a Partici-
pant Information Sheet providing general information 
on the trial, explaining that delivery of LTC reviews 
within the practice is being evaluated using patient self-
reported outcomes and medical record review; and a 
self-completion questionnaire, including a consent form 
and a pre-paid return envelope. A contact number for 
the study team will be included if the patient wishes 
to ask any questions before deciding whether or not to 
participate.
Practices will be asked to invite eight patients per 
week for the duration of the study. The identification of 
dedicated ENHANCE consultations will allow practice 
reception staff to identify and allocate appropriate eligi-
ble patients to the consultations and the nurse to focus 
on handing out the study packs during those consulta-
tions only.
The duration of each LTC review varies according to 
practice and LTC, ranging from 20 to 40 minutes for 
one condition and up to an hour for those with several 
conditions. During both the control and intervention 
periods, practices will be allocated funding to permit 
five minutes to be added to each ENHANCE LTC 
review. This is to enable the practice nurse to intro-
duce the study to patients, hand out the study pack and 
complete the ENHANCE EMIS template (interven-
tion period only). Additional funding will also allow 
a further 10 minutes to be added twice a week for the 
practice nurse to generate a list of eligible participants 
to whom study packs have been provided. This list 
will then be emailed to a National Institute for Health 
Research (NIHR) Clinical Research Network (CRN) 
administrator. An additional 15 minutes will be added 
to the consultation during the intervention phase, as 
outlined below.
Usual care (control)
An initial scoping exercise of the practices within the NHS 
Stoke-on-Trent CCG and the NHS North Staffordshire 
CCG revealed variation in ‘usual care’ between practices. 
Whilst some practices deliver their LTC reviews within 
dedicated clinics, others provide a more ad hoc appoint-
ment system. Whilst we will not ask practices to alter the 
content of their usual LTC reviews during the control 
period, we will be asking that patients included in the 
study are only booked into dedicated study consultations.
The ENHANCE LTC review (intervention)
The ENHANCE LTC review has been co-designed by 
researchers, patients, clinicians, and other stakeholders 
using an implementation of change model and commu-
nity of practice approach. The development work has 
been published elsewhere [41]. During the intervention 
period, practice nurses who have received the study train-
ing will deliver the ENHANCE LTC review during the 
dedicated study consultations, and be supported by the 
specifically designed study ENHANCE EMIS template.
The core components of the ENHANCE LTC review 
are:
 • LTC review consultations set up specifically for the 
research study
 • Usual LTC reviews extended by 15 minutes to 
integrate:
 – Case-finding for anxiety (Generalized Anxiety 
Disorder 2-item [GAD-2] questionnaire) [42]/
depression (two-question Patient Health Ques-
tionnaire [PHQ-2]) [43]/OA-related joint pain 
(any pain in the hands, hips, knees, or feet)
 – Assessment of anxiety (Generalized Anxiety 
Disorder 7-item [GAD-7] questionnaire [44]/
depression (9-question Patient Health Question-
naire [PHQ-9]) [45]/OA-related joint pain (four 
questions guided by NICE 2014 working diagnosis 
of OA [46] (see Figure 2)
 – Negotiation of a management plan which might 
include facilitating self-management support or 
signposting/referral to services within or outside the 
practice
 • An ENHANCE LTC review summary card for 
patients
 • An ENHANCE EMIS template to support the review
 – A modified LTC review template, specifically 
developed for the study, will be embedded within 
the EMIS system at practice level. The prac-
tice nurse will access this template, allowing key 
information to be recorded and the fidelity of the 
training and content of the ENHANCE LTC 
review to be assessed.
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Intervention period
Four GP  practices  from either NHS Stoke-on-Trent or North Staffordshire CCG recruited through
NIHR CRN: West Midlands (GP practice consents as patient guardian)
All four practices start control period for a minimum of 5 weeks
Practices will change from control to intervention in line with a stepped-wedge methodology every 5 weeks
until all practices are delivering the intervention. A washout period (max. 2 weeks) will enable the practice
nurses to receive training before the start of the intervention period
Patient (≥45 years) with a LTC attends ENHANCE
review consultation
Electronic pop-up activated on Read code entry* to
remind nurse to hand out study pack 
Patient (≥45 years) with LTC attends ENHANCE
review consultation
Electronic pop-up activated on Read code entry* to
remind nurse to perform ENHANCE LTC review and
hand out study pack 
Case find for OA-related joint pain, anxiety and
depression
Nurse gives patient the study pack for the research
study and patient receives usual care
Nurse gives patient the study pack for the research
study and patient receives ENHANCE LTC review 
Patient returns phase 1 questionnaire providing consent† medical record review and further contact
EMIS template downloaded from GP practice
Follow-up postal questionnaire at 6 weeks & 6 months.
Participant contacted for potential interview
Eligible patients (≥45 years) with a LTC is booked
into an ENHANCE review consultation
Patient sent
letter to confirm
extended
appointment and
informed of
potential audio
recording
Negative
Eligible patients (≥45 years) with a LTC is booked
into an ENHANCE review consultation
Follow-up postal questionnaire at
6 weeks & 6 months
Randomization
To determine the order of practices moving from control to intervention period
Co
nt
ro
l p
er
io
d
Medical record review at 6 months
Nurse signposts/refers
(as required)
Positive
Figure 2 Flow chart demonstrating recruitment of participants into the ENHANCE trial during the control and intervention periods. Long-term 
conditions (LTC) include asthma, chronic obstructive pulmonary disease, hypertension/ischaemic heart disease, and diabetes.
*Based on pre-determined Read codes.
†Where consent is incomplete; only phase 1 data will be utilized / medical record review will not be sought / no further contact will be made.
CCG, Clinical Commissioning Group; GP, general practitioner; NIHR CRN, National Institute for Health Research Clinical Research Network; 
NHS, National Health Service; OA, osteoarthritis.
Randomization and allocation concealment
As per stepped-wedge design, all practices will deliver 
the trial intervention, but they will be randomized to 
one of four different start dates (approximately 5 weeks 
apart). Randomization of the practices will be con-
ducted by an independent statistician who will sample 
practices without replacement using a random generator 
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in Excel. Each practice will act as its own control by 
delivering usual care for a given period prior to their 
start date of the intervention.
Allocation concealment for the participating general 
practices is not possible, and therefore, to minimize 
recruitment bias, those delivering the intervention (prac-
tice nurses) will not be involved in allocating patients to 
the trial consultations. Eligible participants due for their 
LTC review will be identified by practice administra-
tion staff and allocated an available study appointment.
Trial population
Our trial population consists of adults attending routine 
LTC reviews with concordant conditions, i.e. conditions 
that have shared risk factors. Following randomiza-
tion, practice administrators will invite approximately 
12 patients per week, aged 45 years and over, who are 
due for their LTC review, to study consultations set up 
for the duration of the pilot trial (6 months). Patients 
will be invited to study consultations regardless of pre-
vious medical history of OA, anxiety, and depression. 
ENHANCE appointment slots will be scheduled by 
practice administrators and eligible patients will be allo-
cated an ENHANCE appointment.
Eligibility
Inclusion criteria
 • Registered with the participating GP practice during 
the specified trial period for that practice
 • Aged 45 years and over
 • Patients due for their LTC review for asthma/COPD/
hypertension or ischaemic heart disease/diabetes.
Exclusion criteria
 • Vulnerable patients [e.g. patients on the practice reg-
ister for severe enduring mental ill health (such as 
unstable schizophrenia/bipolar disorder), significant 
cognitive impairment (such as dementia), and/or ter-
minal illness]
 • Patients who reside in a nursing home and/or have 
alternative arrangements for LTC care
 • Patients unable to read and speak English in order to 
give informed consent.
Participant recruitment
All eligible patients booked into the study consulta-
tions will be given a study pack at the beginning of 
their review inviting them to participate in the research. 
Participants will not be individually randomized; par-
ticipants recruited during the control and intervention 
periods of the trial will be asked to take part in a study 
investigating delivery of LTC reviews in primary care, 
consisting of the completion of three self-report ques-
tionnaires (over a period of 6 months). Participants will 
also be asked to provide informed consent to follow-up 
questionnaires, general practice medical record review 
for the duration of the trial follow-up and further con-
tact from the study team about related studies.
The ENHANCE EMIS template can only be acti-
vated and completed once to ensure that patients attend 
only one study consultation for one LTC, hence are only 
invited to participate in the study once, thereby avoiding 
duplicate entries. A list of eligible participants to whom 
study packs have been provided will be generated by 
the practice nurse at the end of each clinic and emailed 
to an NIHR CRN administrator, using a secure ‘nhs.
net’ email account. This will allow for the processing of 
reminders. The GP practices involved in this study have 
formal agreements with the NIHR CRN West Mid-
lands, whereby staff in the NIHR CRN West Midlands 
are contracted to work for the practice, to undertake 
data quality and training functions associated with the 
GP’s use of their computerized clinical systems, and to 
undertake administration tasks and functions associated 
with identifying patients to take part in the research.
Eligible participants will be invited to read the Partic-
ipant Information Sheet, complete the questionnaire and 
consent form, and post them back to the research centre 
using a pre-paid envelope. The Participant Information 
Sheet will provide a contact number for the research 
trial coordinator, should the patient wish to ask any 
questions about the study or clarify the research process 
before deciding whether or not to participate. The same 
procedure will be followed for both the intervention 
and control periods. Similar methods of recruitment 
have been used successfully in previous studies [e.g. the 
Primary Care Osteoarthritis Screening Trial (POST) 
trial ISRCTN: 40721988; the Study of Work and Pain 
(SWAP) trial ISRCTN: 52269669].
The flow chart summarizes the participant recruit-
ment in both the control and intervention periods (see 
Figure 2).
Sample size
We plan to recruit four practices, a number sufficient to 
test the practical organization of running a stepped-wedge 
trial. As this is a pilot trial, a formal sample size calculation 
is not required. However, the number of participants we 
aim to include in the pilot are detailed below.
To achieve a desired final sample size of approxi-
mately 300, we estimate that 800 patients will need to 
be invited between the four practices over the 6-month 
trial period, allowing for approximately 50% (n=400) 
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consenting to participate, of which 75% will provide 
6-month follow-up data. These assumptions are based on 
trials with similar recruitment methodology conducted 
at our research centre that were previously mentioned; 
however, this requires testing in this pilot trial.
Outcomes
A theoretically informed mixed-methods approach 
will be employed to assess both feasibility and research 
method-based outcomes. Data collection methods 
include participant self-reported questionnaires, a gen-
eral practice medical record review, an ENHANCE 
EMIS template, qualitative interviews and audio record-
ings of the ENHANCE LTC review.
This approach will enable insights into the context-
specific processes that influence the application and 
outcomes of the ENHANCE review [34,35]. However, 
a mixed-methods approach can be problematic; there-
fore, an appropriate theoretical framework is required 
to facilitate the integration of bodies of evidence, which 
have distinct philosophical underpinnings [47–49]. 
A critical realist approach provides a platform from 
which not only to recognize and measure the effects of 
interventions using quantitative methods (such as trial 
methodology or questionnaires) but also to qualitatively 
investigate social realities, such as organizations, social 
structures, the actions of agents, and other mechanisms 
which can influence the implementation or outcomes of 
interventions [35,50,51].
A process evaluation will run in parallel to the trial 
and aims to answer the following questions:
1. What components of the ENHANCE LTC review 
were delivered?
2. How was the ENHANCE LTC review delivered?
3. How much was delivered and what happened as a 
result?
This approach will provide insight into both the imple-
mentation and impact of the ENHANCE review on 
patients with LTCs and members of the practice nurs-
ing team (hereafter referred to as ‘practice nurses’). The 
process evaluation objectives are to assess:
 • Feasibility and acceptability of the ENHANCE LTC 
review, with a particular focus on (i) practice nurse 
experiences of delivering the ENHANCE LTC 
review and completing the ENHANCE EMIS tem-
plate; and (ii) participant experiences of receiving the 
ENHANCE LTC review, including experiences of 
treatment burden
 • Fidelity of the practice nurse training delivered
 • Engagement of general practices participating in the 
pilot trial
 • Engagement of participants in the pilot trial and 
through follow-up
 • Evidence of selection bias in the control and interven-
tion phases
 • Recruitment rates in both control and intervention 
periods
 • Follow-up rates at each time point across both control 
and intervention periods.
We will also undertake a research evaluation to explore 
factors that might allow the intervention to be imple-
mented and tested appropriately in a larger RCT by 
exploring the use of specific outcome measures and esti-
mating the parameters needed for a realistic sample size 
calculation.
The research evaluation objectives are to:
 • Examine completion rates of the self-reported out-
come measures (for primary and secondary outcome 
measures)
 • Examine completion rates of the ENHANCE EMIS 
template
 • Estimate the parameters needed for a realistic sam-
ple size calculation for a larger stepped-wedge cluster 
RCT
 • Examine the feasibility of using a stepped-wedge 
design within primary care
 • Provide an indication of the healthcare and societal 
costs of implementing the new intervention in com-
parison with the control group, thereby allowing 
assessment of potential cost-consequences.
Quantitative data collection
Self-reported questionnaires, medical record review, 
and completion of the ENHANCE EMIS template will 
form the basis of the quantitative data collection.
Self-reported questionnaires
Participants in the control and intervention periods will 
be asked to complete self-report questionnaires at three 
phases: immediately after the LTC review (phase 1), 
at 6-week (phase 2), and 6-month (phase 3) follow-
up. Participants will return their questionnaire to the 
research centre in a pre-paid envelope. To maximize 
response rates to the self-report questionnaires, non-
responders at phase 1 will be sent a reminder postcard 
at 1 week and a reminder study pack (invitation letter, 
questionnaire and Participant Information Sheet with 
pre-paid envelope) at 2 weeks. Non-responders at phase 
2 and 3 will be sent a reminder postcard at 2 weeks and a 
reminder study pack (invitation letter and questionnaire 
with pre-paid envelope) at 4 weeks. A minimal data col-
lection (MDC) ‘short’ questionnaire will be sent at 6 
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weeks (with invitation letter and a pre-paid envelope) 
and an MDC telephone call will also be conducted by 
a research nurse for non-responders at 8 weeks (phase 2 
and 3 follow-up).
The phase 1 questionnaire will collect informa-
tion on participant characteristics (e.g. gender, age, 
employment status), allowing for assessment of poten-
tial selection bias by comparing those recruited during 
the control and intervention periods in each practice. 
The phase 1 questionnaire will also provide informa-
tion on any discussions concerning joint pain and/or 
mood, which took place during the LTC review. This 
will allow us to investigate acceptability and feasibil-
ity on the review and ask whether they received any 
advice, written information or onward referrals relat-
ing to lifestyle changes, medication, and other services. 
Completion rates of the validated tools will inform their 
use in a potential larger RCT. The EuroQol 5-dimen-
sion, 5-level (EQ-5D-5L) questionnaire [52,53] will be 
examined as the primary outcome measure for a larger 
RCT. Secondary outcome measures to be examined are 
listed in Table 1.
The ENHANCE team will assess the success of the 
pilot trial using the following criteria, and the out-
come will be reported to the independent Trial Steering 
Committee (TSC). Our success criteria are that we can 
engage GP practices to participate and stay in the trial 
through follow-up (four practices), successfully deliver 
the training to at least one practice nurse per practice, 
and recruit (at least 50% of those invited) and retain 
(75% of those that consent) sufficient participants to the 
research evaluation.
Table 1 summarizes the outcome measures and their 
respective time-points of data collection [44,45,52–56].
Medical record review
General practice medical records of consenting par-
ticipants will be accessed and securely downloaded to 
obtain information on symptoms, diagnoses, prescrip-
tions, investigations, and referrals. Medical record 
review of those who provide consent will be under-
taken for the 6 months between the ENHANCE LTC 
review and follow-up, and will allow the study team to 
examine what activities took place during the reviews, 
whether patients were referred to other specialists (e.g. 
local IAPT services, GP, physiotherapist) and potential 
treatment burden. The data will also allow the study 
team to examine whether appropriate signposting was 
being carried out and whether there were any changes to 
medication during the 6-month trial follow-up. In addi-
tion, data on frequency of consultations, prescription 
use, sickness certification, and secondary care referrals 
will be examined in terms of likely service cost (an addi-
tional question regarding time off work is included in 
the questionnaire to allow assessment of financial impli-
cations due to work absenteeism); these costs will be 
considered alongside all clinical and process outcomes 
to allow an indicated cost–consequence framework to 
inform the suitability of a main trial.
Table 1 Outcome measures and timing of data collection.
Measure Description Data collection timing
Phase 1 Phase 2 Phase2 MDC Phase3 Phase 3 MDC
Primary outcome measures
 Health outcome EQ-5D-5L [52,53] ✓ ✓ ✓ ✓ ✓
Secondary outcome measures
 Severity of depression PHQ-9 [45] ✓ ✓ X ✓ X
 Severity of anxiety GAD-7 [44] ✓ ✓ X ✓ X
 Pain intensity Numerical rating scale (0–10) [54] ✓ ✓ X ✓ X
 ‘Bothersomeness’ (of pain) Single question: 1–5 point scale ✓ ✓ X ✓ X
 Pain interference Single question: 1–5 point scale ✓ ✓ X ✓ X
 Health perceptions Single question: 1–5 point scale ✓ ✓ ✓ ✓ ✓
 Satisfaction of LTC review GPAQ nurse assessment [55] ✓ X X X X
 Content of LTC review Topics covered during the review ✓ X X X X
 Healthcare utilization Healthcare utilization questions X X X ✓ X
 Work performance Time off work X ✓ X ✓ X
Demographics
 Demographics Gender, date of birth ✓ ✓ ✓ ✓ ✓
 Socio-economic status Recent paid job title ✓ ✓ X ✓ X
 Employment Current work situation ✓ ✓ X ✓ X
 Health literacy Questions to assess health literacy [56] ✓ X X X X
EQ-5D-5L, EuroQol 5-dimension, 5-level questionnaire; GAD-7, Generalized Anxiety Disorder 7-item questionnaire; GPAQ, General Practice 
Assessment Questionnaire; LTC long-term condition; MDC, minimum data collection; PHQ-9, 9-question Patient Health Questionnaire.
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Use of the ENHANCE EMIS template
Anonymized data will be collected from medical 
records to examine the use of the ENHANCE EMIS 
template. The proportion of participants that (i) were 
asked the case-finding questions; (ii) reported joint 
pain, anxiety and/or depression; and (iii) were referred 
or signposted will be calculated. Baseline scores of pain 
intensity (numerical rating scale) [54], anxiety (GAD-7) 
[44] and/or depression (PHQ-9) [45] will be examined. 
Types of referral and signposting will also be explored.
Qualitative data collection
A sample of ENHANCE LTC reviews will be audio 
recorded. These data, along with semi-structured inter-
views with patient participants, practice nurses, and GPs, 
will form the basis of the qualitative data collection.
Audio recording of the consultations
A sample of intervention period ENHANCE LTC 
review consultations will be digitally audio recorded, 
allowing fidelity of the training to be assessed. Areas of 
interest will include which elements of the ENHANCE 
LTC review the practice nurses used, whether the 
content of the training was evident in practice nurse 
behaviour, and whether gaps in the ENHANCE LTC 
review could be demonstrated. In addition, fidelity 
checking will enable us to describe how the training 
intervention mapped onto delivery of the ENHANCE 
LTC review in actual clinical practice.
We anticipate asking each practice nurse to audio 
record four or five consultations, 2–4 weeks after com-
pletion of their intervention period training. This will 
generate a minimum of 20 recorded consultations, each 
approximately 30–45 minutes in duration. A digital 
audio recorder will be used and switched on by the prac-
tice nurse (after checking the patient has consented to 
their consultation being audio recorded) at the start of 
the consultation.
For those consultations during which reviews may be 
audio recorded, an additional 10 minutes will be sched-
uled pre-consultation to allow a qualitative researcher 
from the study team to discuss the possibility of audio 
recording, and to obtain initial written consent, if appli-
cable. The researcher will explain to the patient how the 
audio recording links with the wider research study and 
will also provide the patient with a study pack for the trial.
Consenting participants will be given a green post-
card confirming initial consent to audio recording. This 
card will be handed to the practice nurse as an indi-
cation that consent has been given, therefore allowing 
audio recording to proceed. After the consultation, the 
researcher will again discuss consent with the patient 
before they leave the practice, and once more by tel-
ephone 2 days later (at least 48 hours later) to confirm 
the patient still agrees to give consent for the recording 
to be kept and analysed by the study team.
The researcher will also obtain written informed 
consent from the practice nurse for the recording of up 
to five ENHANCE LTC reviews. Consent will also be 
obtained after the audio-recorded consultations and by 
telephone 2 days later (at least 48 hours later) to confirm 
the practice nurse still consents to the recordings being 
kept and analysed by the study team.
Interviews
Semi-structured interviews will be conducted with a 
sample of patient participants, practice nurses deliver-
ing the ENHANCE review and GPs from each practice 
involved in the study. Tape-assisted (or ‘stimulated’) 
recall will be used, where possible, to investigate experi-
ences of delivering and receiving the ENHANCE LTC 
review from the perspective of the practice nurses and 
participants, respectively. This method facilitates respon-
dent recall and helps to anchor respondents’ reflections 
in specific consultations [57].
Interviews with patient participants
A sample of patient participants identified during the 
intervention period will be invited to participate in a 
semi-structured interview. Approximately 20 par-
ticipants (data collection will continue until category 
saturation achieved) will be interviewed ensuring pur-
posive sampling of participants with asthma, COPD, 
hypertension or ischaemic heart disease, and diabetes, 
those who responded in the affirmative to the case-find-
ing questions for OA-related joint pain, anxiety and/
or depression, and those referred onto other services. 
Where possible, we will use extracts of the audio-
recorded consultation to prompt about specific areas of 
the consultation relating to the aims of the ENHANCE 
LTC review and use of the case-finding questions for 
anxiety/depression or OA. These extracts will have 
been selected by the study team prior to the interview.
Overall, the interviews will explore acceptability 
of the ENHANCE review, views on the case-finding 
questions, initial management of newly recognized con-
ditions (referrals and signposting), integration with their 
index LTC, including potential treatment burden, and 
their thoughts on the summary card.
Interviews with practice nurses
Semi-structured telephone or face-to-face interviews 
with the practice nurses will explore how the training 
developed their knowledge and skills to enable them 
to deliver the ENHANCE LTC review, whether the 
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training could be improved, and what factors helped or 
hindered implementation of the ENHANCE review.
All practice nurses trained to deliver the ENHANCE 
LTC review will be invited to participate. A topic guide 
will allow an exploration of the acceptability and oper-
ationalization of the training and ENHANCE LTC 
review and EMIS template. In addition to the use of a 
topic guide, we will use extracts of the audio-recorded 
consultation to prompt discussion about specific areas of 
the consultation relating to the aims of the ENHANCE 
LTC review and use of the case-finding questions for 
anxiety/depression and OA. These extracts will have 
been selected by the study team prior to the interview.
Interviews with GPs
GPs from each of the four practices will be invited to 
participate in a semi-structured interview at the end of 
the recruitment period. Where possible, two GPs from 
each practice will be interviewed to explore the impact 
of the ENHANCE LTC review on the work of the 
practice and the GP.
All interviews and audio recordings will be digi-
tally recorded and the interviews will be professionally 
transcribed verbatim. These methods will allow inves-
tigation of the extent to which the ENHANCE review 
needs modifying to improve either acceptability to 
patient participants and healthcare professionals, or rel-
evance to the primary care LTC review and integrated 
care context of its delivery.
Development of the practice nurse training and 
ENHANCE EMIS template
In line with previous research, the development of the 
practice nurse training and the ENHANCE EMIS 
template will consist of four components [58,59]: (i) 
defining the content, (ii) selecting the behaviour change 
techniques, (iii) deciding on the style of delivery, and 
(iv) addressing local practicalities.
The content of the training and the ENHANCE 
EMIS template will be developed by the study team, 
and informed by the findings from patient and stake-
holder workshops and a practice nurse focus group. The 
behaviour change techniques to be employed within the 
training will be mapped against a Theoretical Domains 
Framework [60] identified during the practice nurse 
focus group [61–63]. In terms of the style of delivery of 
the training, the principles of the Adult Learning The-
ory will be drawn upon as its use is well established in 
the development of courses that support continued pro-
fessional development [64]. Cochrane Effective Practice 
and Organisation of Care Group’s reviews and principles 
of context-bound communication skills training [65] 
will also be used to inform the style of delivery.
Finally, the practical implications of delivering the 
training and embedding the ENHANCE EMIS template 
within the four practices will be considered. The study 
team will need to take into account the large number of 
demands already on the practice and work with them to 
address and agree practicalities, such as the location, dura-
tion, and timing of the training, and when the ENHANCE 
EMIS template can be put in place. It is anticipated that 
the training will take place in-practice on a one-to-one or 
small-group basis over 2 half days and will include men-
toring from those with expertise in OA and mental health.
We plan to work with a minimum of eight practice 
nurses (two per practice). Training will take place dur-
ing a 2-week washout period immediately following the 
control period, the duration of which is predetermined 
by randomization. Nurses from each practice will be 
trained to deliver the ENHANCE LTC review which 
will be delivered during the ensuing intervention period, 
and for the remainder of the trial. It is hoped that by 
training more than one practice nurse per general prac-
tice, recruitment can continue throughout the duration 
of the trial. The training will be preceded by a 1-hour 
briefing session, available to all practice staff, which will 
include an overview of the trial and an update of current 
NICE guidance for OA and anxiety and depression.
Adverse events
Serious adverse events (SAEs) include death, hos-
pitalization, significant disability or incapacity, any 
life-threatening circumstance, or any other medically 
significant occurrence. All practice staff involved in the 
trial will report immediately to the Principal Investiga-
tor (PI) if any identified SAE is experienced by a trial 
participant. The PI will assess whether the event was 
related to or resulted from any of the trial procedures 
or interventions, according to the process laid out in 
the Keele CTU Standard Operating Procedures. Any 
SAE considered to be related to the trial procedures 
will be reported to the main Research Ethics Commit-
tee by the PI within 15 days of their awareness of the 
event. In addition, all such events will be reported to 
the trial sponsor, TSC, and Data Monitoring Commit-
tee (DMC). This is deemed a low-risk trial, as we are 
investigating the feasibility of enhancing current LTC 
reviews by incorporating evidence-based management 
of OA-related joint pain, anxiety, and depression.
Analysis
Quantitative data
Analysis of the quantitative data will be exploratory and 
provide further data on the feasibility and acceptability of 
the ENHANCE LTC review and EMIS template. Specifi-
cally, descriptive statistics (numbers and percentages, means 
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and standard deviations, and medians and interquartile 
range) will be used to describe the content of the EMIS 
template for those in the intervention period of the trial, 
and the rates of prescription and referrals over 6 months 
for those consenting to medical record review. Participant 
characteristics, self-reported at phase 1, will be compared 
by treatment period, by GP practice, and by practice nurse 
to explore the balance of patient characteristics by these 
stratified variables. The percentage of participants con-
senting to take part in the study will also be reported for 
each treatment period, along with follow-up rates for the 
6-week and 6-month follow-up questionnaires. We will 
compare recruitment rates and baseline characteristics of 
participants to assess for potential selection bias. Follow-up 
data will also be examined in relation to patient character-
istics to allow potential attrition bias to be assessed.
Findings from the pilot study will also inform changes in 
the trial design, recruitment processes, data collection pro-
cesses, and outcome measures used, that may be required, 
should the team move to a larger RCT. Specifically, we 
will explore the suitability of the trial design by assessing 
the degree of correlation between the self-reported and 
consultation-based GAD-7 [44] and PHQ-9 [45] outcome 
measures. Any constraints imposed by the study design 
should be evident from this comparison; a high correlation 
is desirable. Possible constraints will be further explored 
by examining the average time taken for participants to 
return the phase 1 questionnaire to see how close this is to 
the date of the initial GP consultation. We will also report 
completion rates of the self-reported outcome measures, to 
identify any that are poorly completed, and adapt the con-
tent of the self-reported questionnaire accordingly.
Data from the pilot study will also be used to inform 
a sample size calculation for the main trial by fitting ran-
dom effects models for the primary outcome of interest 
(the EQ-5D-5L [52,53]) at the 6-week and 6-month 
time points. Models will include fixed effects for treat-
ment period (control or intervention) and time, with time 
defined as the step number in the stepped-wedge design, 
from 0 to 4, along with a random effect to represent the 
GP practice that the patient belongs to [66]. The impact 
of adjusting for the baseline measure for the outcome of 
interest as a fixed effect, and the nurse who delivered 
the intervention, will also be explored. The treatment 
effect estimates from these models will not be inter-
preted; however, these models will be used to explore a 
potential range of estimates for the intra-class correlation 
coefficient, i.e. the proportion of the individual variance 
attributable to cluster membership [67] that is needed for 
a sample size calculation for a main trial. This estimate 
will be viewed cautiously, however, given that there are 
only four practices included in the pilot trial.
We have designed the pilot study to include a washout 
period between the control and intervention phases of the 
study, both to ensure the nurse training could be fitted 
into existing workloads and to minimize any delay in the 
full treatment effect being realised, i.e. to allow time for 
the nurse to be sufficiently trained to deliver the treatment 
intervention consistently over time for every patient. We 
therefore hypothesize that the within-GP practice mean 
of the primary outcome measure at the 6-week and the 
6-month follow-up will not differ greatly, depending on 
the time period when the intervention was delivered. This 
will be tested using descriptive statistics and by exploring 
the coefficients of the term representing ‘time’ in the ran-
dom effects models used to gain estimates for a sample size 
calculation for a main trial.
We will also use data from the pilot study to explore 
the feasibility of a subgroup analysis for a main trial, 
with the subgroup defined as those participants with co-
existing symptoms of anxiety/depression or pain at phase 
1 who could potentially benefit from the intervention. 
The feasibility of this subgroup analysis will be explored 
by reporting the percentage of participants in each treat-
ment period with co-existing symptoms of anxiety/
depression or pain to explore if it is feasible for treat-
ment effects to be calculated only for those participants 
with the potential to benefit from the intervention. It is 
anticipated that the proportion of such participants will 
be similar between treatment periods; therefore, their 
contribution to the mean effect in each period will be 
similar; this will be tested in the pilot study data.
Qualitative data
One or more researchers will examine the audio record-
ings of the consultations and use a previously developed 
tick box scoresheet to assess whether key components of 
the ENHANCE consultation were demonstrated by the 
practice nurse.
A tape-assisted recall (or ‘stimulated recall’) approach 
[57] will be used in the semi-structured practice nurse 
and participant interviews, with extracts of the consul-
tations being played to stimulate discussion and explore 
extracts of interest within the consultation. Transcripts 
of the practice nurse, patient, and GP interviews will 
be analysed by members of the study team, adopting a 
constant comparison approach [68,69], with concep-
tual themes generated through initial coding of text 
segments, followed by re-coding and memo writing. 
Consensus meetings between the qualitative study team 
will allow discussion and agreement of overarching the-
matic interpretations. A framework approach will then 
be used to facilitate interpretation of the data set [70].
Discussion
Improving the management of people with LTCs has 
been a key priority of the UK NHS for more than 2 
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decades [1], with primary care increasingly seen as the 
optimal setting to deliver care. Yet whilst living with 
multiple LTCs is increasingly the norm in patients, 
guidelines and service delivery typically remain focused 
on single-disease management. For some LTCs, adher-
ence to clinical guidelines is incentivized through 
inclusion in the QOF component of the General Practice 
contract, linking financial reward directly to targeted 
performance. For some conditions not included in QOF 
(e.g. OA, chronic pain, anxiety), and/or those condi-
tions with more subjective outcomes (e.g. depression), 
care frequently remains suboptimal and health needs 
often go unidentified [71,72]. As Goodwin et al. noted, 
‘chronic disease management approaches that identify 
patients on the severity of a single condition may miss 
multimorbid patients who stand to benefit greatly from 
improved co-ordination of care’ [6].
Musculoskeletal conditions and mental health prob-
lems are common and frequently co-exist, both with 
each other and with other LTCs. People with comorbid 
pain and mental health problems have higher levels of 
disability, a poorer prognosis, and increased healthcare 
costs; yet the detection and management of these condi-
tions is challenging and frequently suboptimal. Whilst it 
is recognized that a shift towards integrated care is essen-
tial if we are to ensure a holistic approach addressing both 
physical and mental health problems [18], there is little 
direct evidence demonstrating what would constitute 
high quality care or how this may be implemented [6].
The ENHANCE study will examine the feasibil-
ity and acceptability of an integrated approach to LTC 
management, tackling the under-diagnosis and under-
management of OA-related pain and anxiety and/
or depression in patients with other LTCs in primary 
care. Satisfaction of those participants who received 
the ENHANCE review should be at least as acceptable 
as that of those who received usual care (by compar-
ing mean scores on the General Practice Assessment 
questionnaire) [55]. Treatment fidelity will further be 
explored in terms of evaluation of modalities received. 
Recruitment uptake, follow-up rates, and characteristics 
of trial participants should be similar in both treatment 
periods of the study, thus safeguarding against poten-
tial selection bias and ensuring validity of any trial data. 
We will consider a difference in recruitment or follow-
up rate of up to 10% to represent an acceptable level of 
deviation for the pilot trial.
Ethics approval
The study has been approved by the Greater Manchester 
East Research Ethics Committee (REC reference: 15/
NW/0335).
Trial monitoring
The ENHANCE trial will be monitored in line with 
the protocol and Keele’s Clinical Trials Unit Standard 
Operating Procedures. An independent TSC will moni-
tor the progress of the trial and the DMC will monitor 
the safety of participants and data integrity. Monitoring 
will also be undertaken by the approving Research Eth-
ics Committee in the format of annual progress reports 
and the NIHR Collaborations for Leadership in Applied 
Health Research and Care West Midlands in the format 
of quarterly progress reports.
Public and patient involvement
The trial design and processes have been informed by 
user involvement in line with our Centre’s strong com-
mitment to involving the public in research, following 
INVOLVE’s recommendations. Thirteen members of 
the public attended our patient advisory group meeting 
held in June 2014 and two members of the public were 
involved in each of our three stakeholder workshops (in 
June, July, and September 2014) at which the research 
question, aim of the trial and design of the interven-
tion were discussed and agreed. Two individuals from 
the patient advisory group have agreed to be members 
of our TSC. The remaining members of the patient 
advisory group assessed our participant information 
(letters of invitation, Participant Information Sheets, 
questionnaires and summary card) and their feedback 
was incorporated in the final versions. All research 
users are supported by our Centre’s Public and Patient 
Involvement Coordinator through regular meetings and 
an annual conference at Keele, with funding support 
through the Centre’s Centre of Excellence award from 
Arthritis Research UK.
Trial sponsor: Keele University
The sponsor will have no role in the design and analysis 
of the data.
Acknowledgements
The authors would like to thank Dr Andrew Morden, the 
Research Users’ Group, the National Institute for Health 
Research (NIHR) Clinical Research Network West 
Midlands and administrative staff at Keele University’s 
Research Institute for Primary Care and Health Sciences 
for their support and assistance with this study. The authors 
would also like to thank all of the staff at the participating 
general practices and members of the TSC and DMC for 
their valuable input in study design and conduct.
The ENHANCE pilot trial protocol  147
© 2015 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2015;5:135–149
Conflicts of interest
The authors have no conflicts of interest to declare.
Funding
This paper presents independent research jointly 
funded by the NIHR Collaborations for Leadership 
in Applied Health Research and Care West Midlands 
and the Arthritis Research UK Primary Care Centre 
of Excellence (grant reference 20202). C.D.M., K.S.D., 
E.L.H., C.J., and A.G.F. are part funded by the NIHR 
Collaborations for Leadership in Applied Health 
Research and Care West Midlands. C.D.M. is also 
funded by the NIHR School for Primary Care Research 
and a NIHR Research Professorship in General Practice 
(NIHR-RP-2014-04-026). K.S.D. is also funded by a 
Knowledge Mobilisation Research Fellowship (KMRF-
2014-03-002). The views expressed in this paper are 
those of the author(s) and not necessarily those of the 
NHS, the NIHR, or the Department of Health.
References
1 National Health Service (NHS) England. NHS Outcomes Frame-
work – 5 domains resources. Domain 2: enhancing quality of life 
for people with long-term conditions. Available from: https://www.
england.nhs.uk/resources/resources-for-ccgs/out-frwrk/dom-2/ 
[last accessed Sep 24, 2015].
2 National Health Service (NHS) England. Enhancing the quality of 
life for people living with long term conditions – The House of 
Care. Available from: https://www.england.nhs.uk/house-of-care/ 
[last accessed Sep 24, 2015].
3 Improving Chronic Illness Care. The Chronic Care Model, 1998. 
Available from: http://www.improvingchroniccare.org/index.
php?p=The_Chronic_Care_Model&s=2 [last accessed Sep 24, 2015].
4 Department of Health, UK. The NHS and Social Care long 
term conditions model, 1997. Available from: http://webarchive.
nationalarchives.gov.uk/+/www.dh.gov.uk/en/Healthcare/Long-
termconditions/DH_4130652 [last accessed Sep 24, 2015].
5 Clark D, Layard R, Smithies R, Richards DA, Suckling R, Wrighte 
B. Improving access to psychological therapy: initial evaluation of 
two UK demonstration sites. Behav Res Ther 2009;47:910–20. View 
Item.
6 Goodwin N, Curry N, Naylor C, Ross S, Duldig W. Managing 
people with long-term conditions. An inquiry into the quality of 
general practice in England. The Kings Fund, 2010. Available from: 
http://www.kingsfund.org.uk/sites/files/kf/field/field_document/
managing-people-long-term-conditions-gp-inquiry-research-pa-
per-mar11.pdf [last accessed Nov 25, 2015].
7 Salisbury C, Johnson L, Purdy S, Valderas J, Montgomery AA. 
Epidemiology and impact of multimorbidity in primary care: a ret-
rospective cohort study. Br J Gen Pract 2011;61:582,e12–21. View 
Item.
8 Duerden M, Avery T, Payne R. Polypharmacy and medicines opti-
misation: making it safe and sound. The Kings Fund, 2013. Available 
from: http://www.kingsfund.org.uk/publications/polypharmacy-
and-medicines-optimisation [last accessed Nov 25, 2015].
9 Tran V-T, Montori VM, Eton DT, BaruchD, Falissard B, Ravaud 
P. Development and description of measurement properties of an 
instrument to assess treatment burden among patients with multiple 
chronic conditions. BMC Med 2012;10:68. View Item.
10 May CR, Eton DT, Boehmer K, Gallacher K, Hunt K, MacDonald 
S, et al. Rethinking the patient: using Burden of Treatment Theory 
to understand the changing dynamics of illness. BMC Health Serv 
Res 2014;14:281. View Item.
11 O’Brien R, Wyke S, Guthrie B, Watt G, Mercer S. An “endless strug-
gle”: a qualitative study of general practitioners’ and practice nurses’ 
experiences of managing multimorbidity in socio-economically 
deprived areas of Scotland. Chronic Illn 2011;7:45–59. View Item.
12 Steinman MA, Hanlon JT. Managing medications in clinically com-
plex elders. J Am Med Assoc 2010;304:1592–601. View Item.
13 May C, Montori VM, Mair FS. We need minimally disruptive medi-
cine. Br Med J 2010;339:b2803. View Item.
14 Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical 
practice guidelines and quality of care for older patients with mul-
tiple comorbid diseases. J Am Med Assoc 2005;294:716–24. View 
Item.
15 Shadmi E, Freund T. Targeting patients for multimorbid care man-
agement interventions: the case for equity in high-risk patient 
identification. Int J Equity Health 2013;12:70. View Item.
16 Smith SM, Bayliss EA, Mercer SW, Gunn J, Vestergaard M, Wyke S, 
et al. How to design and evaluate interventions to improve outcomes 
for patients with multimorbidity. J Comorbidity 2013;3:10–7. View 
Item.
17 Porcheret M, Jordan K, Jinks C, Croft P. Primary Care 
 Rheumatology Society. Primary care treatment of knee pain – a 
survey in older adults. Rheumatology (Oxford) 2007;46:1694–
700. View Item.
18 Coventry P, Hays R, Dickens C, Bundy C, Garrett C, Cherrington 
A, et al. Talking about depression: barriers to managing depression in 
people with long term conditions in primary care. BMC Fam Pract 
2011;12:10. View Item.
19 van Dijk GM, Veenhof C, Schellevis F, Hulsmans H, Bakker JPG, 
Arwert H, et al. Comorbidity, limitations in activities and pain in 
patients with osteoarthritis of the hip or knee. BMC Musculoskelet 
Disord 2008;9:95. View Item.
20 Kadam UT, Jordan K, Croft PR. Clinical morbidity in patients with 
osteoarthritis: a case control study of general practice consulters in 
England and Wales. Ann Rheum Dis 2004;63:408–14. View Item.
21 Arthritis Research UK. Osteoarthritis in general practice: data and 
perspectives, 2013. Available from: https://www.keele.ac.uk/media/
keeleuniversity/ri/primarycare/pdfs/Keele_Data_Report.pdf [last 
accessed Dec 3, 2015].
22 van’t Veer-Tazelaar PJ, van Marwijk H, Jansen A, Rijmen F, Kostense 
P, van Oppen P, et al. Depression in old age (75+), the PIKO study. 
J Affect Disord 2008;106:295–9. View Item.
23 Katon W, Ciechanowski P. Impact of major depression on chronic 
medical illness. J Psychosom Res 2002;53:859–63. View Item.
24 Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krish-
nan KR, et al. Mood disorders in the medically ill: scientific review 
and recommendations. Biol Psychiatry 2005;58:175–89. View Item.
25 Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, 
Yohannes AM, et al. Anxiety and depression in COPD: current 
understanding, unanswered questions, and research needs. Chest 
2008;134(4 Suppl.):43S–56S. View Item.
148  Emma L. Healey et al.
© 2015 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2015;5:135–149
26 Kroenke K, Outcalt S, Krebs E, Bair MJ, Wu J, Chumbler N, et al. 
Association between anxiety, health-related quality of life and func-
tional impairment in primary care patients with chronic pain. Gen 
Hosp Psychiatry 2013;35:359–65. View Item.
27 Alderson SL, Foy R, Glidewell L, House AO. Patients understanding 
of depression associated with chronic physical illness: a qualitative 
study. BMC Fam Pract 2014;15:37. View Item.
28 Broadbent J, Maisey S, Holland R, Steel N. Recorded quality of 
primary care for osteoarthritis: an observational study. Br J Gen Pract 
2008;58:839–43. View Item.
29 Chew-Graham CA, Hunter C, Langer S, Stenhoff A, Drinkwater J, 
Guthrie E, et al. How QOF is shaping primary care review consulta-
tions: a longitudinal qualitative study. BMC Fam Pract 2013;14:103. 
View Item.
30 Knowles S, Chew-Graham CA, Coupe N, Adeyemi I, Keyworth C, 
Thampy H, et al. Better together? A naturalistic qualitative study 
of inter-professional working in collaborative care for co-morbid 
depression and physical health problems. Implement Sci 2013;8:110. 
View Item.
31 Smith SM, Soubhi H, Fortin M, Hudon C, O’Dowd T. Managing 
patients with multimorbidity: systematic review of interventions in 
primary care and community settings. Br Med J 2012;345:e5205. 
View Item.
32 Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, 
Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard pro-
tocol items for clinical trials. Ann Intern Med 2013;158:200–7. View 
Item.
33 Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot 
or feasibility study? A review of current practice and editorial policy. 
BMC Med Res Methodol 2010;10:67. View Item.
34 Craig P, Dieppe P, Macintyre S, Mitchie S, Nazareth I, Petticrew M. 
Developing and evaluating complex interventions: the new Medical 
Research Council guidance. Br Med J 2008;337. View Item.
35 Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. 
Process evaluation of complex interventions: UK Medical Research 
Council (MRC) guidance, 2014. Available from: http://decipher.
uk.net/wp-content/uploads/2014/11/MRC-PHSRN-Process-
evaluation-guidance.pdf [last accessed Sep 24, 2015].
36 Lancaster GA, Dodd SR, Williamson PR. Design and analysis of 
pilot studies: recommendations for good practice. J Eval Clin Pract 
2004;10:307–12. View Item.
37 Grant A, Treweek S, Dreischulte T, Foy R, Guthrie B. Process evalu-
ations for cluster-randomised trials of complex interventions: a 
proposed framework for design and reporting. Trials 2013;14:15. 
View Item.
38 O’Cathain A, Hoddinott P, Lewin S, Thomas KJ, Young B, Adamson 
J, et al. Maximising the impact of qualitative research in feasibil-
ity studies for randomised controlled trials: guidance for researchers. 
Pilot and Feasibility Studies 2015;1:32. View Item.
39 Brown CA, Lilford RJ. The stepped wedge trial design: a systematic 
review. BMC Med Res Methodol 2006;6:54. View Item.
40 Eldridge SM, Ashby D, Feder GS. Informed patient consent to par-
ticipation in cluster randomized trials: an empirical exploration of 
trials in primary care. Clin Trials 2005;2:91–8. View Item.
41 Jinks C, Morden A, Chew-Graham C, Porcheret M, Finney A, 
Dziedzic K, et al. Integrating care for joint pain and anxiety and 
depression into reviews for long-term conditions: The Enhance 
Study. Rheumatology 2015;54(Suppl 1):i67. View Item.
42 Kroenke K, Spitzer RL, Williams JB, Monahan PO, Löwe B. Anxiety 
disorders in primary care: prevalence, impairment, comorbidity, and 
detection. Ann Intern Med 2007;146:317–25. View Item.
43 Kroenke K, Spitzer RL, Williams JB. The Patient Health Ques-
tionnaire-2: validity of a two-item depression screener. Med Care 
2003;41:1284–92.
44 Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for 
assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 
2006;22:1092–7. View Item.
45 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief 
depression severity measure. J Gen Intern Med 2001;16:606–13. 
View Item.
46 National Institute for Health and Care Excellence (NICE). Osteoar-
thritis: care and management. London: NICE; 2014. Available from: 
https://www.nice.org.uk/guidance/cg177 [last accessed Nov 25, 
2015].
47 Blackwood B, O’Halloran P, Porter S. On the problems of mixing 
RCTs with qualitative research: the case of the MRC framework 
for the evaluation of complex healthcare interventions. J Res Nurs 
2010;15:511–21. View Item.
48 Clark AM, MacIntyre PD, Cruickshank J. A critical realist approach 
to understanding and evaluating heart health programmes. Health 
2007;11:513–39. View Item.
49 Marchal B, Westhorp G, Wong G, Van Belle S, Greenhalgh T, Kegels 
G, et al. Realist RCTs of complex interventions – an oxymoron. Soc 
Sci Med 2013;94:124–8. View Item.
50 Bonell C, Fletcher A, Morton M, Lorenc T, Moore L. Realist ran-
domised controlled trials: a new approach to evaluating complex public 
health interventions. Soc Sci Med 2012;75:2299–306. View Item.
51 Bonell C, Fletcher A, Morton M, Lorenc T, Moore L. Methods don’t 
make assumptions, researchers do: a response to Marchal et al. Soc 
Sci Med 2013;94:81–2. View Item.
52 EuroQol Group. EuroQol–a new facility for the measurement of 
health-related quality of life. Health Policy 1990;16:199–208.
53 Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. 
Development and preliminary testing of the new five-level version of 
EQ-5D (EQ-5D-5L). Qual Life Res 2011;20:1727–36. View Item.
54 Ostelo RW, de Vet HC. Clinically important outcomes in low back 
pain. Best Pract Res Clin Rheumatol 2005;19:593–607. View Item.
55 Mead N, Bower P, Roland M. The General Practice Assessment 
Questionnaire (GPAQ) – development and psychometric character-
istics. BMC Fam Pract 2008;9:13. View Item.
56 Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients 
with inadequate health literacy. Fam Med 2004;36:588–94.
57 Cape J, Geyer C, Barker C, Pistrang N, Buszewicz M, Dowrick C, 
et al. Facilitating understanding of mental health problems in GP 
consultations: a qualitative study using taped-assisted recall. Br J Gen 
Pract 2010;60:837–45. View Item.
58 French SD, Green SE, O’Connor DA, McKenzie JE, Francis JJ, 
Michie S, et al. Developing theory-informed behaviour change 
interventions to implement evidence into practice: a systematic 
approach using the Theoretical Domains Framework. Implement 
Sci 2012;7:38. View Item.
59 Porcheret M, Main C, Croft P, McKinley R, Hassell A, Dziedzic K. 
Development of a behaviour change intervention: a case study on the 
practical application of theory. Implement Sci 2014;3:42. View Item.
60 Cane J, O’Connor D, Michie S. Validation of the theoretical domains 
framework for use in behaviour change and implementation 
research. Implement Sci 2012;24:37. View Item.
61 Bussières AE, Patey AM, Francis JJ, Sales AE, Grimshaw JM; Can-
ada PRIme Plus Team, et al. Identifying factors likely to influence 
compliance with diagnostic imaging guideline recommendations 
for spine disorders among chiropractors in North America: a focus 
group study using the Theoretical Domains Framework. Implement 
Sci 2012;31:82. View Item.
62 Penn L, Dombrowski SU, Sniehotta FF, White M. Participants’ 
perspectives on making and maintaining behavioural changes 
in a lifestyle intervention for type 2 diabetes prevention: a quali-
tative study using the theory domain framework. BMJ Open 
2013;3:e002949. View Item.
The ENHANCE pilot trial protocol  149
© 2015 The Authors
 Published by Swiss Medical Press GmbH | www.swissmedicalpress.com Journal of Comorbidity 2015;5:135–149
63 McSherry LA, Dombrowski SU, Francis JJ, Murphy J, Martin CM, 
O’Leary JJ, et al. ‘It’s a can of worms’: understanding primary care 
practitioners’ behaviours in relation to HPV using the theoretical 
domains framework. Implement Sci 2012;7:73. View Item.
64 Brookfield SD. Understanding and facilitating adult learning: a 
comprehensive analysis of principles and effective practices. San 
Francisco: Jossey-Bass Inc. Publishers; 1986.
65 Rollnick S, Kinnersley P, Butler C. Context-bound communica-
tion skills training: development of a new method. Med Educ 
2002;36:377–83. View Item.
66 Hussey MA, Hughes JP. Design and analysis of stepped wedge cluster 
randomised trials. Contemp Clin Trials 2007;28:182–91. View Item.
67 Hemming K, Marsh J. A menu-driven facility for sample-size calcula-
tions in cluster randomized controlled trials. Stata J 2013;13:114–35.
68 Glaser BG. The constant comparative method of qualitative analysis. 
Soc Probl 1965;12:436–45. View Item.
69 Hallberg LRM. The “core category” of grounded theory: Mak-
ing constant comparisons. Int J Qual Stud Health Well-being 
2006;1:141–8. View Item.
70 Ritchie J, Spencer L. Qualitative data analysis for applied policy 
research. In: Bryman A, Burgess RG, editors. Analyzing qualitative 
data. 1st Ed. Oxon: Routledge; 1994. pp. 173–94.
71 Steel N, Maisey S, Clark A, Fleetcroft R, Howe A. Quality of clini-
cal primary care and targeted incentive payments: an observational 
study. Br J Gen Pract 2007;57:449–54.
72 Lester H, Hannon KL, Campbell S. Identifying unintended con-
sequences of quality indicators: a qualitative study. BMJ Qual Saf 
2011;20:1057–61. View Item.
